Physician profile
Michelle E Legall
NPI 1619179447
$5,836.67
in general payments reported to CMS, 2019-2025
42 companies · $11.49 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $805 · 2021: $1,117 · 2022: $1,635 · 2023: $203 · 2024: $499 · 2025: $11.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,291.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $588.63 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $462.71 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $335.24 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $254.01 | 2019-2021 | |
| Horizon Therapeutics Plc | $218.48 | 2019-2022 | |
| Inspire Medical Systems, INC. | $202.82 | 2022-2023 | Inspire |
| Abbott Laboratories | $201.93 | 2021-2024 | Freestyle Libre 3 |
| Optinose US, INC. | $201.13 | 2019-2023 | |
| Glaxosmithkline, LLC. | $195.36 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.63 | 2020-2024 | Xifaxan, Trulance |
| Abbvie INC. | $179.80 | 2021-2024 | |
| Gilead Sciences, INC. | $146.96 | 2019 | |
| Currax Pharmaceuticals LLC | $134.13 | 2019-2021 | |
| Axsome Therapeutics, INC. | $118.69 | 2024 | Auvelity |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Legall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.